Lipitor (Atorvastatin) News and Research

RSS

Atorvastatin (INN) (Lipitor, Pfizer), is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Atorvastatin inhibits HMG-CoA reductase, the rate-determining enzyme located in hepatic tissue that produces mevalonate, a small molecule used in the synthesis of cholesterol and other mevalonate derivatives. This lowers the amount of cholesterol produced which in turn lowers the total amount of LDL cholesterol. Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2006 sales of US$12.9 billion, Lipitor is the largest-selling drug in the world.

Lowering of LDL level shows limited benefit for patients with previous heart attack

Patients who have had a heart attack and are treated with a high dose of a statin drug did not have significant reduction in the primary outcome of major cardiac events (coronary death, nonfatal acute heart attack, or cardiac arrest with resuscitation), but did appear to have reduced risk when certain secondary outcomes (composite end points of any coronary heart disease event) were examined, according to a study in the November 16 issue of JAMA.

26 Nov 2005

Torcetrapib - Lipitor drug combo shows promise

According to drug company Pfizer the results of two mid-stage studies on its experimental cholesterol drug torcetrapib, combined with its cholesterol drug Lipitor, were so promising that the company will continue into the final stage.

15 Nov 2005

Tricor disappoints in diabetes trial

Researchers say the results of a large trial of a drug to lower triglycerides failed in its primary goal of significantly reducing heart attacks and coronary deaths among patients with type II diabetes.

15 Nov 2005

Cholesterol lowering drugs do not appear to decrease the risk of melanoma

No clear evidence exists that some widely-prescribed cholesterol-lowering drugs can decrease the risk of melanoma, a deadly and malignant skin cancer, according to a new review of recent studies.

7 Nov 2005

Very low LDL cholesterol levels appear to be safe for heart patients on statin therapies

"There was no apparent safety concern for patients whose resultant LDL on intensive therapy was lower than current guidelines. There was a trend toward improved clinical outcomes in the lowest LDL groups," said Stephen D. Wiviott, M.D., from Brigham and Women's Hospital in Boston, Massachusetts.

11 Oct 2005

Strokes and heart attacks can be prevented in people with high blood pressure

Most strokes and heart attacks in people with high blood pressure can be abolished by simply combining effective, modern blood pressure lowering drugs with treatment to reduce cholesterol.

6 Sep 2005

New study supporting the importance of aggressive cholesterol-lowering

New clinical data shows that intensive cholesterol-lowering to targets below currently recommended levels significantly reduces the risk of heart attack and stroke for people with diabetes and heart disease.

14 Jun 2005

Most serious side effects in statins may be higher in one of the newest drugs, rosuvastatin (Crestor)

A post-market analysis of cholesterol-lowering drugs called statins indicates that some of the most serious side effects may be higher in one of the newest drugs, rosuvastatin (Crestor). The drug is the strongest statin available because it has the greatest effect per milligram on low-density lipoprotein ("bad" cholesterol).

26 May 2005

New cholesterol drug Crestor causes safety concerns

A study by a leading medical journal has concluded that AstraZeneca's controversial drug Crestor produces more than twice as many side effects as other common cholesterol lowering treatments.

24 May 2005

Statins appear to lessen chance of developing breast cancer

According to a new study women who are taking the cholesterol-lowering drugs called statins, such as Lipitor or Mevacor, appear to have much less chance of developing breast cancer.

16 May 2005

Fat-fighting drugs may be a far riskier business than they seem

Experts are warning that despite the fact that obesity is one of the biggest preventable causes of death, fat-fighting drugs may be a far riskier business than they seem, particularly for investors.

11 May 2005

FDA to change regulations regarding side-effect information in drug ads

The Food and Drug Administration is about to make it easier for you to understand both the benefits and risks of a prescription medication, it was revealed at the Second Annual Medical Liaison Seminar sponsored here by Scientific Advantage LLC.

2 May 2005

Antibiotics do not prevent heart attacks

Clinicians and researchers have found that more than three quarters of heart attack patients have been infected with chlamydia pneumoniae - a bacteria found in arteries of heart attack patients - and multiple studies have found this can double the risk of developing subsequent heart attacks.

27 Apr 2005

Favorable Austrian ruling for Ranbaxy on Atorvastatin

Ranbaxy Pharmaceuticals, Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (Ranbaxy), hasy announced that it successfully invalidated claims 1-3 (all claims sought to be invalidated) of Austrian Patent No. AT E 207 896 as anticipated by, and as lacking inventive step over, respectively, a Pfizer-owned published patent application and a Pfizer owned patent, as reflected by a decision released by the Austrian Patent Office.

30 Mar 2005

Lipitor patients who reduced 'bad' cholesterol show decrease in heart attack and stroke

Patients with coronary heart disease who took Pfizer's cholesterol-lowering medicine Lipitor (atorvastatin calcium) and lowered their cholesterol to well below recommended levels experienced significantly fewer heart attacks and strokes than those who only lowered their cholesterol to recommended levels

8 Mar 2005

Blood pressure treatment could cut risk of strokes and heart attacks

A new treatment strategy for hypertension can cut the risk of strokes by around 25 percent and coronary events by around 15 percent according to the preliminary results of a major international trial announced at the American College of Cardiology Late Breaking Clinical Trials II Meeting in Orlando today.

8 Mar 2005

St. John's wort increases effectiveness of Plavix

The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds.

6 Mar 2005

No to over the counter statin!

Last Friday an FDA expert panel voted overwhelmingly against the over-the-counter sale of Merck's cholesterol lowering drug Mevacor (lovastatin). Mevacor is one of a number of drugs known as "statins" which are widely considered to be the most effective drugs for the treatment of high cholesterol. Statins work by inhibiting a liver enzyme used in the manufacture of cholesterol.

17 Jan 2005

Statins lower C-reactive protein (CRP), a major new risk factor for heart disease marked by inflammation

For years, doctors have believed that statin therapy lowers the risk of heart disease solely by lowering levels of cholesterol.

9 Jan 2005

New guidelines for treating diabetes

Every year, the American Diabetes Association (ADA) issues Clinical Practice Recommendations, a series of updated recommendations to help health care providers treat people with diabetes using the most current research available.

7 Jan 2005